Form 4: Apogee CEO Sells Shares Under Pre-Arranged 10b5-1 Plan

Apogee Therapeutics CEO Michael Henderson sold 19,000 shares of common stock on January 14, 2026, under a pre-arranged 10b5-1 trading plan.

Summary

• Michael Thomas Henderson, the Chief Executive Officer and a Director of Apogee Therapeutics, Inc. (APGE), reported the sale of common stock.
• A total of 19,000 shares of common stock were disposed of on January 14, 2026.
• The transactions were executed pursuant to a Rule 10b5-1 trading plan, which was adopted on August 13, 2025.
• The shares were sold in multiple transactions at weighted average prices ranging from $78.64 to $83.79 per share.
• Following these reported transactions, Mr. Henderson directly beneficially owns 1,192,987 shares of Apogee Therapeutics common stock.

Sentiment

Score: 4

Explanation: The CEO's sale of shares, while executed under a pre-arranged 10b5-1 plan, represents a reduction in insider ownership. While the pre-planned nature mitigates the negative signal, it is not a positive indicator of management's increasing confidence in the near-term stock price.

Positives

• The reported transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025, indicating the sales were pre-scheduled and not based on immediate, non-public information.

Negatives

• Michael Henderson, the Chief Executive Officer and a Director, disposed of a total of 19,000 shares of Apogee Therapeutics common stock.
• The sales occurred at weighted average prices ranging from $78.64 to $83.79 per share.

Stakeholder Impact

• Shareholders may perceive the insider sale as a neutral to slightly negative signal, although the pre-arranged 10b5-1 plan suggests the decision was not based on recent non-public information.

Key Dates

Recommendation

The CEO's sale of shares, while significant in volume, was conducted under a pre-arranged 10b5-1 trading plan. This indicates the decision was made in advance and not based on immediate, non-public information, thereby mitigating the typical negative signal associated with insider selling. This transaction alone does not provide a strong catalyst for a 'buy' or 'sell' decision, leading to a 'hold' recommendation.

Keywords

Apogee Therapeutics, APGE, insider trading, Form 4, stock sale, CEO, Michael Henderson, 10b5-1 plan